throbber
4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`CHOOSING ZYTIGA®/
`
`ABOUT ZYTIGA® (abiraterone
`acetate)
`Is ZYTIGA Right for You?
`
`gilirZYTIGA® Was the #1 Prescribed Oral Medication
`for Metastatic Castration -Resistant Prostate
`Cancer in 20151
`
`ZYTIGA® is an oral, once -daily prescription medication used in combination
`with prednisone. ZYTIGA® is used to treat men with a type of prostate cancer
`called mCRPC (metastatic castration -resistant prostate cancer). This cancer is
`resistant to medical (eg, hormonal) or surgical treatments that lower
`testosterone and has spread to other parts of the body.
`
`ZYTIGA® is the first oral, once -daily medication for mCRPC.
`
`By choosing ZYTIGA ®, you are joining the more than 80,000
`men in the United States who have been prescribed
`ZYTIGA®.
`
`*Estimate is based on sales and use data from April 2011 to December 2015.
`
`References: 1. Data on file. Janssen Biotech, Inc.
`
`https://www.zytiga.com/choosing-zytigatresults-of-zytiga
`
`1/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 1
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`CHOOSING ZYTIGA®/
`
`HOW ZYTIGA® WORKS
`
`Understanding mCRPC
`
`Before learning how treatment with ZYTIGA® works, it's helpful to understand
`how mCRPC affects your body.
`
`Watch a video about mCRPC
`
`Understanding How ZYTIGA® Works
`
`ZYTIGA® works by interrupting the androgen- making process at an important
`step. It inhibits androgen at 3 sources -the testes, the adrenal glands, AND the
`tumor itself.
`
`https: / /www.zytiga.com/ choosing- zytiga/results -of- zytiga
`
`2/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 2
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`ZYTIGA® is different from some medicines that only decrease androgen
`production in the testes and do not affect the adrenal glands or prostate tumor
`tissue.
`
`The Role of Prednisone With ZYTIGA®
`
`While taking ZYTIGA® you will also take prednisone. Because of the way
`ZYTIGA® works, certain side effects may occur. Prednisone may help
`decrease the occurrence and severity of these side effects. For more
`information, talk to your doctor.
`
`Take your prednisone exactly how your healthcare provider tells you. Do not
`stop taking your prescribed dose of ZYTIGA® or prednisone without talking to
`your healthcare provider first.
`
`Hear Ron's Story
`
`Hear patients share their experiences.
`
`https: / /www.zytiga.com/ choosing- zytiga/results -of- zytiga
`
`3/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 3
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`Watch a ZYTIGA® Story
`
`CHOOSING ZYTIGA®/
`
`RESULTS OF ZYTIGA®
`
`Confidence in Results of ZYTIGA®
`
`ZYTIGA® was approved by the FDA and proven effective in 2
`clinical studies
`
`In a clinical study of 1,088 men with metastatic castration -resistant prostate
`cancer, whose disease had progressed while on androgen deprivation
`therapy (ADT) and had not received prior chemotherapy, the results
`measured:
`
`Overall Survival
`
`How long men lived taking ZYTIGA® + prednisone vs placebo +
`prednisone
`
`In the clinical study, certain men who had received ZYTIGA® +
`prednisone lived longer than men taking placebo + prednisone.
`
`https://www.zytiga.com/choosing-zytiga/results-of-zytiga
`
`4/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 4
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`The median overall survival was 34.7 months for the group of men
`who received ZYTIGA® + prednisone vs 30.3 months for those men
`taking placebo + prednisone.
`
`Please speak to your doctor about what this may mean to you.
`View clinical study information on overall survival
`
`Disease Progression
`
`Length of time men lived without their disease getting worse or dying
`while taking ZYTIGA® + prednisone vs placebo + prednisone as
`measured by imaging studies
`
`In the same study, at a planned analysis, fewer men had progression
`as measured by imaging studies in the group who received ZYTIGA® +
`prednisone compared to the group who had received placebo +
`prednisone.
`
`65% (354 of 546) of men who received ZYTIGA® + prednisone had
`progression, as measured by imaging studies
`71 % (387 of 542) of men who received placebo + prednisone had
`progression, as measured by imaging studies
`
`Please speak to your doctor about what this may mean to you.
`View clinical study information on disease progression
`
`Delay to Chemotherapy
`
`The time to start chemotherapy in patients taking ZYTIGA® +
`prednisone vs placebo + prednisone as measured by imaging studies
`
`Also in this study, the median time to starting chemotherapy for the
`group of men taking ZYTIGA® plus prednisone was 25.2 months
`compared to 16.8 months in the group taking placebo + prednisone.
`View clinical study information on time to chemotherapy
`
`Additionally, ZYTIGA® was studied in a clinical trial of over 1,000 men with
`metastatic castrate -resistant prostate cancer who received chemotherapy
`
`https: / /www.zytiga.com/ choosing- zytiga/results -of- zytiga
`
`5/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 5
`
`

`

`4/3/2017
`
`Clinical Studies ZYTIGA® (abiraterone acetate)
`
`with docetaxel.
`
`Androgen deprivation -A treatment to suppress or block the production or action of male
`hormones. (National Cancer Institute: NO Dictionary of Cancer Terms. Bethesda, MD: National
`Cancer Institute. 2013. Available at www.cancer.gov /dictionary. Accessed 5/13/2016.)
`Placebo -An inactive substance or treatment that looks the same as, and is given the same way as,
`an active drug or treatment being tested. (National Cancer Institute: NCI Dictionary of Cancer Terms.
`Bethesda, MD: National Cancer Institute. 2013. Available at www.cancer.gov /dictionary. Accessed
`5/13/2016.)
`
`Median overall survival -The length of time from either the date of diagnosis or the start of a
`clinical study or treatment for a disease, such as cancer, that half of the patients in a group of
`patients diagnosed with the disease are still alive. In a clinical trial, measuring the median overall
`survival is one way to see how well a new treatment works. Also called median survival. (National
`Cancer Institute: NCI Dictionary of Cancer Terms. Bethesda, MD: National Cancer Institute. 2013.
`Available at www.cancer.gov /dictionary. Accessed 5/13/2016.)
`
`The most common side effects of ZYTIGA® include:
`
`Weakness
`joint swelling or pain
`Swelling in your legs or feet
`Hot flushes
`Diarrhea
`Vomiting
`Cough
`High blood pressure
`Shortness of breath
`Urinary tract infection
`Bruising
`Low red blood cells (anemia) and low blood potassium levels
`High blood sugar levels, high blood cholesterol and triglycerides
`Certain other abnormal blood tests
`
`Tell your healthcare provider if you have any side effect that bothers you or
`that does not go away.
`
`Review a list of the potential side effects of ZYTIGAC'
`
`View Potential Side Effects
`
`https: / /www.zytiga.com/ choosing -zytiga/results -of- zytiga
`
`6/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 6
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`You can get help identifying your cost support
`options to help pay for your ZYTIGA®
`
`Learn How
`
`WHAT IS ZYTIGA ®?
`ZYTIGA® (abiraterone acetate) is a prescription medicine that is used along with
`prednisone. ZYTIGA® is used to treat men with castration -resistant prostate cancer
`(prostate cancer that is resistant to medical or surgical treatments that lower
`testosterone) that has spread to other parts of the body.
`
`Important Safety Information
`Who should not take ZYTIGA® (abiraterone acetate)?
`
`Do not take ZYTIGA® if you are pregnant or may become pregnant. ZYTIGA® may harm
`your unborn baby. Women who are pregnant or who may become pregnant should not
`touch ZYTIGA® without protection, such as gloves.
`
`ZYTIGA® is not for use in women or children. Keep ZYTIGA® and all medicines out of
`the reach of children.
`
`Before you take ZYTIGA ®, tell your healthcare provider if you:
`Have heart problems
`Have liver problems
`Have a history of adrenal problems
`Have a history of pituitary problems
`Have any other medical conditions
`Plan to become pregnant (See "Who should not take ZYTIGA ® ? ")
`Are breastfeeding or plan to breastfeed. It is not known if ZYTIGA® passes into your
`breast milk. You and your healthcare provider should decide if you will take ZYTIGA®
`or breastfeed. You should not do both. (See "Who should not take ZYTIGA ® ? ")
`Take any other medicines, including prescription and over -the -counter medicines,
`vitamins, and herbal supplements. ZYTIGA® can interact with many other medicines.
`
`If you are taking ZYTIGA ®:
`
`Take ZYTIGA® and prednisone exactly as your healthcare provider tells you.
`Take your prescribed dose of ZYTIGA® one time a day. Your healthcare provider may
`change your dose if needed.
`Do not stop taking your prescribed dose of ZYTIGA® or prednisone without talking to
`your healthcare provider first.
`
`https://wwwzytiga.com/choosing-zytiga/results-of-zytiga
`
`7/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 7
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`Take ZYTIGA® on an empty stomach. Do not take ZYTIGA® with food. Taking
`ZYTIGA® with food may cause more of the medicine to be absorbed by the body than
`is needed and this may cause side effects.
`No food should be eaten 2 hours before and 1 hour after taking ZYTIGA ®.
`Swallow ZYTIGA® tablets whole. Do not crush or chew tablets.
`Take ZYTIGA® tablets with water.
`Your healthcare provider will do blood tests to check for side effects.
`Men who are sexually active with a pregnant woman must use a condom during and
`for one week after treatment with ZYTIGA ®. If their female partner may become
`pregnant a condom and another form of birth control must be used during and for
`one week after treatment with ZYTIGA ®. Talk with your healthcare provider if you have
`any questions about birth control.
`If you miss a dose of ZYTIGA® or prednisone, take your prescribed dose the following
`day. If you miss more than 1 dose, tell your healthcare provider right away.
`
`ZYTIGA® may cause serious side effects including:
`High blood pressure (hypertension), low blood potassium levels (hypokalemia),
`and fluid retention (edema).
`Tell your healthcare provider if you get any of the following symptoms:
`
`Dizziness
`heartbeats
`Feel faint or lightheaded
`Headache
`Confusion
`Muscle weakness
`Pain in your legs
`Swelling in your legs or feet
`
`Adrenal problems may happen if you stop taking prednisone, get an infection, or are
`under stress.
`Liver problems. You may develop changes in liver function blood tests. Your
`healthcare provider will do blood tests to check your liver before treatment with
`ZYTIGA® and during treatment with ZYTIGA ®. Liver failure may occur, which can lead
`to death. Tell your healthcare provider if you notice any of the following changes:
`Yellowing of the skin or eyes
`Darkening of the urine
`Severe nausea or vomiting
`
`The most common side effects of ZYTIGA® include:
`
`Weakness
`Joint swelling or pain
`Swelling in your legs or feet
`Hot flushes
`Diarrhea
`
`https://www.zytiga.comichoosing-zytigairesults-of-zytiga
`
`8/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 8
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`Vomiting
`Cough
`High blood pressure
`Shortness of breath
`Urinary tract infection
`Bruising
`Low red blood cells (anemia) and low blood potassium levels
`High blood sugar levels, high blood cholesterol and triglycerides
`Certain other abnormal blood tests
`
`Tell your healthcare provider if you have any side effect that bothers you or that does not
`go away.
`
`THESE ARE NOT ALL THE POSSIBLE SIDE EFFECTS OF ZYTIGA ®.
`FOR MORE INFORMATION, ASK YOUR HEALTHCARE PROVIDER OR PHARMACIST.
`Tell your healthcare provider about all the medicines you take, including
`prescription and over -the -counter medicines, vitamins, and herbal supplements.
`
`ZYTIGA® can interact with other medicines.
`
`You should not start or stop any medicine before you talk with the healthcare provider
`that prescribed ZYTIGA ®.
`
`Know the medicines you take. Keep a list of them with you to show to your healthcare
`provider and pharmacist when you get a new medicine.
`
`Call your doctor for medical advice about side effects. You are encouraged to report
`negative side effects of prescription drugs to the FDA.
`Visit www.fda.gov /medwatch, or call 1- 800 -FDA -1088 (1- 800 -332 -1088).
`
`051 527- 1 6041 8
`
`© Janssen Biotech. Inc. 2016. All Rights Reserved.
`
`This site is published by Janssen Biotech. Inc., which is solely responsible for its contents. The
`material on this site is intended only as informational or as an educational aid and it is not
`intended to be taken as medical advice. The ultimate responsibility for patient care resides with a
`healthcare professional.
`
`This information is intended for the use of patients and caregivers in the United States and Puerto
`Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary
`from country to country. The Prescribing Information included here may not be appropriate for
`use outside the United States and Puerto Rico.
`
`Capitalized product names are trademarks of Janssen Biotech, Inc.
`
`Legal Notice I Privacy Policy I Contact Us I Unsubscribe I Site Map
`
`Last updated July 2016. 056663-161121
`https: /lwww.zyti ga.com /choosi ng- zytiga/results- of- zytiga
`
`9/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 9
`
`

`

`4/3/2017
`
`Clinical Studies I ZYTIGA® (abiraterone acetate)
`
`https://www.zytiga.com/choosing-zytiga/results-of-zytiga
`
`10/10
`
`MYLAN PHARMS. INC. EXHIBIT 1089 PAGE 10
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket